InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $6 Million Registered Direct Offering
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, closed its previously announced registered direct offering of 4 million shares of common stock (or pre-funded warrants) at $1.50 per share. H.C. Wainwright & Co. served as exclusive placement agent. Gross proceeds totaled approximately $6 million before fees and expenses, with net proceeds intended for working…